In a recent multicenter, single-arm, open-label Phase II clinical trial (SHC013-II-01, NCT03823807) (Xiong et al., 2022) conducted in China, rilertinib demonstrated promising efficacy in 227 patients with EGFR T790M mutation–positive NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.